Dataset Information

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

ABSTRACT:

Unlabelled

Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated.

Methods

We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP.

Results

Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than those who never used cannabis (mean years = 31.4, SD = 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% CI: 1.16-1.74; P < .001). This association remained significant after controlling for gender (HR = 1.39; 95% CI: 1.11-1.68; P < .001). Those who had started cannabis at age 15 or younger had an earlier onset of psychosis (mean years = 27.0, SD = 6.2; median years = 26.9) than those who had started after 15 years (mean years = 29.1, SD = 8.5; median years = 27.8; HR = 1.40; 95% CI: 1.06-1.84; P = .050). Importantly, subjects who had been using high-potency cannabis (skunk-type) every day had the earliest onset (mean years = 25.2, SD = 6.3; median years = 24.6) compared to never users among all the groups tested (HR = 1.99; 95% CI: 1.50- 2.65; P < .0001); these daily users of high-potency cannabis had an onset an average of 6 years earlier than that of non-cannabis users.

Conclusions

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

SUBMITTER: Di Forti M

PROVIDER: S-EPMC4193693 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Di Forti Marta M Sallis Hannah H Allegri Fabio F Trotta Antonella A Ferraro Laura L Stilo Simona A SA Marconi Arianna A La Cascia Caterina C Reis Marques Tiago T Pariante Carmine C Dazzan Paola P Mondelli Valeria V Paparelli Alessandra A Kolliakou Anna A Prata Diana D Gaughran Fiona F David Anthony S AS Morgan Craig C Stahl Daniel D Khondoker Mizanur M MacCabe James H JH Murray Robin M RM

Schizophrenia bulletin 20131217 6

<h4>Unlabelled</h4>Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated.<h4>Methods</h4>We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP.<h4>Results</h4>Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than th ...[more]

PMID: 24345517

Similar Datasets

Project description:BackgroundCannabis is one of the most widely used substances worldwide. Heavy use is associated with an increased risk of cannabis use disorders, psychotic disorders, acute cognitive impairment, traffic injuries, respiratory problems, worse pregnancy outcomes, and there are indications for genotoxic and epigenotoxic adverse effects. International regulation of medical and non-medical cannabis use is changing rapidly and substantially, highlighting the importance of robust public health monitoring. This study aimed to describe the trends of key public health indicators in European Union (27 member states + UK, Norway and Turkey) for the period 2010 to 2019, their public health implications, and to identify the steps required to improve current practice in monitoring of cannabis use and harm in Europe.MethodsData on four key cannabis indicators (prevalence of use, prevalence of cannabis use disorder [CUD], treatment rates, and potency of cannabis products) in Europe were extracted from the United Nations Office on Drugs and Crime, European Monitoring Centre for Drugs and Drug Addiction and the Global Burden of Disease study. For prevalence of use and CUD, the first and last available estimate in each country were compared. For treatment rates and cannabis potency, linear regression models were conducted.FindingsBetween 2010 and 2019, past-month prevalence of cannabis use increased by 27% in European adults (from 3·1 to 3·9%), with most pronounced relative increases observed among 35-64 year-olds. In 13 out of 26 countries, over 20% of all past-month users reported high-risk use patterns. The rate of treatment entry for cannabis problems per 100,000 adults increased from 27·0 (95% CI: 17·2 to 36·8) to 35·1 (95% CI: 23·6 to 46·7) and has mostly plateaued since 2015. Modest increases in potency were found in herbal cannabis (from 6·9% to 10·6% THC) while median THC values tripled in cannabis resin (from 7·6% to 24·1% THC).InterpretationIn the past decade, cannabis use, treatment rates and potency levels have increased in Europe highlighting major concerns about the public health impact of cannabis use. Continued monitoring and efforts to improve data quality and reporting, including indicators of high-risk use and cannabis-attributable harm, will be necessary to evaluate the health impact of international changes in cannabis regulation.FundingThis study received no specific funding.

Dataset Information

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Unlabelled

Methods

Results

Conclusions

Publications

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets